Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1990 Jun;66(776):471–473. doi: 10.1136/pgmj.66.776.471

Raised dopamine metabolites in a case of malignant paraganglioma.

C M Florkowski 1, D J Fairlamb 1, M G Freeth 1, S A Taylor 1, A Taylor 1, C Weinkove 1, A G Jacobs 1
PMCID: PMC2429596  PMID: 2216999

Abstract

This paper describes the case of a malignant retroperitoneal paraganglioma with extensive metastases. The patient presented with a supraclavicular mass and an absence of hypertension. Exclusively raised dopamine metabolites were detected which may be a marker of a malignant process and account for the lack of hypertension.

Full text

PDF
471

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ATTIA A., GOLDEN R. L., ZIFFER H. Nonchromaffin-staining functional tumor of the organs of Zuckerkandl. N Engl J Med. 1961 Jun 1;264:1130–1133. doi: 10.1056/NEJM196106012642204. [DOI] [PubMed] [Google Scholar]
  2. Enquist R. W., Tormey D. C., Jenis E. H., Warkel R. L. Malignant chemodectoma of the superior mediastinum with elevated urinary homovanillic acid. Chest. 1974 Aug;66(2):209–211. doi: 10.1378/chest.66.2.209. [DOI] [PubMed] [Google Scholar]
  3. Feldman J. M., Blalock J. A., Zern R. T., Shelburne J. D., Gaede J. T., Farrell R. E., Wells S. A., Jr Deficiency of dopamine-beta-hydroxylase. A new mechanism for normotensive pheochromocytomas. Am J Clin Pathol. 1979 Aug;72(2):175–185. doi: 10.1093/ajcp/72.2.175. [DOI] [PubMed] [Google Scholar]
  4. GJESSING L. R. STUDIES OF FUNCTIONAL NEURAL TUMORS. VI. BIOCHEMICAL DIAGNOSIS. Scand J Clin Lab Invest. 1964;16:661–669. doi: 10.3109/00365516409055231. [DOI] [PubMed] [Google Scholar]
  5. ISAACSON C., ROSENZWEIG D., SEFTEL H. C. Malignant pheochromocytoma of the organs of Zuckerkandl. Arch Pathol. 1960 Dec;70:725–729. [PubMed] [Google Scholar]
  6. MCMILLAN M. Identification of hydroxytyramine in a chromaffin tumour. Lancet. 1956 Aug 11;271(6937):284–284. doi: 10.1016/s0140-6736(56)92083-9. [DOI] [PubMed] [Google Scholar]
  7. Price S., Davenport K., Berg J. D. Determination of urinary 3-methoxy-4-hydroxymandelic and 3-methoxy-4-hydroxyphenylacetic acids by fused silica capillary gas chromatography. Ann Clin Biochem. 1986 May;23(Pt 3):351–353. doi: 10.1177/000456328602300318. [DOI] [PubMed] [Google Scholar]
  8. Proye C., Fossati P., Fontaine P., Lefebvre J., Decoulx M., Wemeau J. L., Dewailly D., Rwamasirabo E., Cecat P. Dopamine-secreting pheochromocytoma: an unrecognized entity? Classification of pheochromocytomas according to their type of secretion. Surgery. 1986 Dec;100(6):1154–1162. [PubMed] [Google Scholar]
  9. Serrano P. A., Chavez-Lara B., Sanchez-Torres G. Dopamine excretion in benign pheochromocytoma. Biomedicine. 1978 Nov;29(7):229–231. [PubMed] [Google Scholar]
  10. Tippett P. A., McEwan A. J., Ackery D. M. A re-evaluation of dopamine excretion in phaeochromocytoma. Clin Endocrinol (Oxf) 1986 Oct;25(4):401–410. doi: 10.1111/j.1365-2265.1986.tb01706.x. [DOI] [PubMed] [Google Scholar]
  11. VON EULER U. S. Adrenaline and noradrenaline; distribution and action. Pharmacol Rev. 1954 Mar;6(1):15–22. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES